Inhibrx Biosciences, Inc. INBX
Set alert
81.75 USD +9.59 +13.29%
As of Nov 3, 2:43 PM ET
71.16 Day range 82.56
57.30 52-week range 155.29
- YTD
- +3.48%
- 1 year
- +0.38%
- Open
- 71.16
- Prev close
- 72.16
- Mkt cap
- 1.20B
- Vol
- 270.08K
- Avg vol
- 303.33K
- EPS
- -8.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 71.16
- High
- 82.56
- Forward P/E
- -8.24
- Beta
- 4.04
- Short ratio
- 13.62
- Inst. own
- 90.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2026
- 50-d avg
- 102.34
- 200-d avg
- 92.14
- 1y target
- 266.67
6M chart
Events in this range
- May 14, 2026Earnings: -2.15; estimate -2.37; surprise 9.28%
- Aug 13, 2026Earnings: -2.34; estimate -2.28; surprise -2.63%
- Aug 24, 2026Rating: HC Wainwright & Co. · — → Buy
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 3 months ago |
Newest 20 of 27.
Key statistics
- Market cap
- 1.06B
- Enterprise value
- 1.10B
- Trailing P/E
- 0.00
- Forward P/E
- -8.24
- PEG ratio
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -8.88
- Beta
- 4.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -85.10M
- Total cash
- 133.34M
- Total debt
- 181.63M
- Return on equity
- -1773.60%
- Shares outstanding
- 14.72M
- Short % of float
- 31.00%
- 50-day average
- 102.34
- 200-day average
- 92.14
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 266.67 +226.2% upside
Now 81.75
- Target (low)
- 230.00
- Target (mean)
- 266.67
- Target (high)
- 325.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 13, 2026
Expected Nov 13, 2026. Consensus EPS estimate -2.36.
Financials — quick view
INBX Revenue — quarterly 0
INBX Net income — quarterly -36.65M
INBX EPS — quarterly -2.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -2.45 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -2.28 | -2.34 | -0.06 | -2.63% |
| May 14, 2026 | Mar 31, 2026 | -2.37 | -2.15 | +0.22 | +9.28% |
| Mar 19, 2026 | Dec 31, 2025 | -2.08 | -2.11 | -0.03 | -1.44% |
| Nov 14, 2025 | Sep 30, 2025 | -2.08 | -2.28 | -0.20 | -9.62% |
| Aug 13, 2025 | Jun 30, 2025 | -2.92 | -1.85 | +1.07 | +36.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | init | — | Buy |
| Apr 8, 2026 | Stifel | init | — | Buy |
| Aug 22, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| May 15, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| Mar 18, 2025 | Citizens Capital Markets | reit | Market Perform | Market Perform |
| Jan 22, 2025 | JMP Securities | reit | Market Perform | Market Perform |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inhibrx.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
- Inhibrx Announces Participation in Upcoming Scientific Conferences
- Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
- Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
- Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
- Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares
- Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock
- Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Your note
Sign in to keep a note on INBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORSYTH DOUGLAS | Director | Purchase | Sep 7, 2026 | 0 |
| KAYYEM JON FAIZ | Director | Purchase | Sep 22, 2026 | 0 |
| LAPPE MARK | Chief Executive Officer | Purchase | Oct 13, 2026 | 0 |
| MANHARD KIMBERLY J | Director | Sale | Sep 14, 2026 | 0 |
| VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 8.89% | 1,308,051 | 94.39M | Jun 29, 2026 |
| Perceptive Advisors Llc | 8.82% | 1,297,763 | 93.65M | Jun 29, 2026 |
| Sanofi | 7.87% | 1,157,926 | 83.56M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 7.64% | 1,123,929 | 81.10M | Jun 29, 2026 |
| HighTower Advisors, LLC | 5.92% | 870,551 | 62.82M | Jun 29, 2026 |
| Bank of America Corporation | 5.72% | 841,141 | 60.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.51% | 369,641 | 26.67M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.40% | 353,292 | 25.49M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.21% | 324,794 | 23.44M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.68% | 247,839 | 17.88M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 109,883 | 7.93M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.71% | 103,938 | 7.50M | Jul 30, 2026 |